Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $19.6B | $35.5B | $37.0B | $40.0B | $42.4B | $42.9B | $45.2B | $48.8B | $46.2B | $41.6B | $42.5B | $38.7B | $38.4B | $40.9B | $42.1B | $42.1B | $42.7B | $46.3B | $47.8B | $49.8B |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Sanofi's last 12-month Revenue is $64.6B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Sanofi's Revenue growth was 32.5%. The average annual Revenue growth rates for Sanofi have been 14.4% over the past three years, 9.2% over the past five years.
Over the last year, Sanofi's Revenue growth was 32.5%, which is higher than industry growth of 0.1%. It indicates that Sanofi's Revenue growth is Good.